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Abstract
In this paper, we address the research question
of which integration points in the German Fast-Track
process are particularly well suited for the integration
of evaluation platforms for digital health applications.
For this purpose, possible integration points are first
identified and then analyzed with the help of a utility
analysis with regard to the posed research question.
Finally, a recommendation for action is made based on
the results of the conducted utility analysis.
1. Introduction
As digitalization in medicine continues to grow,
digital health applications (in German Digitale
Gesundheitsanwendungen - in short DiGA) are expected
to gain importance in the future [1]. According to the
World Health Organization (WHO), DiGAs have the
potential to transform the face of global healthcare [2].
In this context, the quality assessment and evaluation
of DiGAs is crucial, as only verified quality can ensure
good medical care.
In Germany, the introduction of the Digital Health
Act (in German Digitale-Versorgungs-Gesetz - in short
DVG) has made prescribable DiGAs eligible for
reimbursement since December 19, 2019. For a
DiGA to be prescribable, it must be included in the
DiGA directory. The costs for prescribable DiGAs are
covered by the health insurance companies. In order
to be included in the DiGA directory, a DiGA must
successfully pass the Fast-Track process of the German
Federal Ministry for Drugs and Medicines (BfArM),
which is an accreditation process for quality assurance.
The DiGAs has also to demonstrate positive care effects
in a suitable form, e.g., by additional studies. With the
concept of prescription and reimbursement of accredited
DiGAs by health insurances, Germany is a pioneer
among the OECD countries [1] [4].
Besides the accreditation processes, there are
independent evaluation platforms for DiGAs where
the evaluation can make detailed statements about the
quality of a DiGA and thus positively impacts the
accreditation process.
In contrast to accreditation, which in the context
of quality assurance only checks whether a condition
is fulfilled, an evaluation can make gradual statements
about determinable facts. Under the assumption that
the evaluation of a quality criterion can be represented
as a monotonous, continuous function, a transformation
of the evaluation into an accreditation is possible by
the discretization of the function in histogram-like
stages that logically build on each other along the
evaluation dimension of the respective quality criterion,
as illustrated in Figure 1.
Therefore, we consider the question at which
integration point in the German Fast-Track process
DiGA evaluation platforms should be integrated to be
able to make optimal use of the resulting positive
effects?
This paper presents a utility analysis to determine
optimal integration points of DiGA evaluation platforms
into the DiGA accreditation processes, and taking the





Figure 1. Relationship between a continuous
evaluation function and discrete quality levels (QL)
derived by decision boundaries for accreditation.
German Fast-Track [5] process as an example. First, the
used criteria, scales, and perspectives of the used utility
analysis are introduced. Then, possible integration
points in the German Fast-Track process are identified.
Subsequently, the criteria are evaluated in the form of an
author discussion for each identified integration point.
Afterward, different perspectives are presented in the
context of the utility analysis. Finally, the results of the
utility analysis are compared, and a recommendation for
the integration of DiGA evaluation platforms into the
German Fast-Track process is formulated.
This paper is structured as follows. Section
2 provides an overview of related work focused
on the accreditation and evaluation approaches of
DiGAs, including a brief explanation of the German
Fast-Track process, which is used as a model reference.
Furthermore, approaches for the evaluation of process
integrations are presented. In Section 3, the methods
used to identify and evaluate appropriate integration
points of DiGA evaluation platforms into DiGA
accreditation processes are presented. Integration
points for DiGA evaluation platforms into the German
Fast-Track process are identified in Section 4. Section
5 discusses and concludes the evaluation of the selected
criteria for each integration point. In Section 6, we draw
our conclusion.
2. Related work
2.1. Accreditation of DiGAs for the purpose of
quality assurance
The Food and Drug Administration (FDA)
accreditation process classifies DiGAs into three
risk classes (low, middle, high) with associated
regulatory requirements based on the underlying utility.
The FDA verifies that these requirements have been
fully validated and implemented. Depending on the
class, scientific evidence of the DiGA’s safety and
effectiveness may be required.
In comparison, the German Digital Health
Care Act (Digitale-Versorgung-Gesetz) and the
Digital Health Applications Ordinance (Digitale
Gesundheitsanwendungen-Verordnung) specify that
for a DiGA to be included in the DiGA directory, it
must first undergo a review by the Federal Institute
for Drugs and Medical Devices (Bundesinstitut für
Arzneimittel und Medizinprodukte - BfArM). This
review is called the German Fast-Track process, which
is illustrated in Figure 2. During the Fast-Track process,
Figure 2. Integration points for mHealth evaluation
platforms in the German Fast-Track process [5].
the BfArM first reviews for at least three months a© the
specified requirements for safety, functionality, quality,
interoperability, data protection, and data security are
implemented. In Step b©, the DiGA has to proof
positive care effects or medical benefit in terms of
procedural and structural improvement. Three possible
cases may arise within this review. Either the DiGA
already fulfills all criteria and can be included directly
in the DiGA directory, or if this is not the case, the
DiGA can be rejected directly. Furthermore, in case
of doubt regarding the positive care effect, the BfArM
retains the right to include the DiGA only provisionally
in the DiGA directory and test it for a positive care
effect in a 12-month trial phase c©. After that, the DiGA
is either added to the DiGA directory or rejected. If
the DiGA is included in the DiGA directory, physicians
and psychotherapists can prescribe it to their patients by
prescription, and a statutory health insurance company
covers the costs.
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2.2. Evaluation of DiGAs for a differentiated
assessment of their quality
To date, there are several different approaches to
determine the quality of a DiGA. One widely used
approach is the determination of the quality of DiGAs
by answering questionnaires. Besides this widely
used approach, other approaches provide guidelines or
define rules, or heuristics, that DiGA vendors should
follow. In [6], the authors provide a broad overview of
methodological and practical approaches to evaluate the
quality of DiGAs.
In [7], the authors present eight principles that
should lead to high quality medical websites (or
applications). The presented HONcode includes the
principles Authoritative, Complementarity, Privacy,
Attribution, Justifiability, Transparency, Financial
disclosure, and Advertising policy. Medical websites
(or applications) that successfully undergo voluntary
audits by Health On the Net Foundation (HON) receive
a quality seal to help physicians and patients navigate
the digital health market.
In [8] and [9], the authors present a questionnaire
to determine the quality of a DiGA in two versions.
The Medication Adherence Rating Scale (MARS) is a
questionnaire aimed at physicians that determines the
quality of a DiGA in five domains. The User Medication
Adherence Rating Scale (uMARS) is based on the
Medication Adherence Rating Scale, but it addresses
patients or users of DiGAs instead of physicians.
In [10], the Fraunhofer FOKUS presents a catalog
of questions suitable for the evaluation of the quality
of DiGAs. The questions cover a wide range of issues
related to the topics of medical content, ethics, security,
technical features, and privacy. The AppKri question
catalog does not address a specific target group and does
not serve as a questionnaire for evaluating the quality
of DiGAs on its own but as a toolbox for creating such
questionnaires.
In [11], [12], and [13], the authors present
an expert-based multidisciplinary approach to the
evaluation of DiGAs. The approach follows the idea
of a multidisciplinary evaluation with experts from the
four domains of medical Content, Usability, Security,
and Law, of DiGAs. The quality evaluation of DiGAs
is performed with the CUSL score, which also can
be used as a quality seal, comparable to the HON
quality seal. Furthermore, the concept of an DiGA
evaluation platform is presented, which provides quality
information of DiGAs with a structured taxonomy to
patients, physicians, and health insurances.
Beyond the approaches mentioned above to
determine the quality of DiGAs, some platforms
concretely implement the quality evaluation of DiGAs.
Weisse Liste [14] is a German DiGA evaluation
platform operated by a subsidiary of Bertelsmann
Verlag. The platform enables physicians and
patients to search for DiGAs and provides detailed
information about the quality of DiGAs through
voluntarily produced quality reports by DiGA vendors.
Furthermore, the platform offers additional services,
such as a physician search or functions for finding
hospitals and care homes.
KVAppRadar [15] by Central Institute for the
Provision of Health Care by Statutory Health Insurance
Physicians in the Federal Republic of Germany
Foundation under civil law (Zentralinstitut für die
kassenärztliche Versorgung in der Bundesrepublik
Deutschland Stiftung des bürgerlichen Rechts) is
a German DiGA evaluation platform that provides
DiGA evaluation data only for health insurances and
physicians. As core functions, the platform enables
physicians a structured discussion and evaluation
of DiGAs and the communication of the involved
stakeholders.
ORCHA [16] is a British evaluation platform aimed
at patients, physicians, and DiGA vendors. The platform
offers DiGA vendors the opportunity to evaluate their
DiGAs independently by medical experts. Reviewed
DiGAs are presented on the ORCHA platform with
detailed information about their quality. Physicians
and patients can search for and inform themselves
about DiGAs via the platform. Beyond the one-time
evaluation of a DiGA, the platform ensures a continuous
quality evaluation of all tested DiGAs.
2.3. Process integration
The evaluation of processes within the context
of process management is required in order to be
able to identify, evaluate and thus compare possible
enhancements. The accreditation often used for this
purpose can be of too limited precision.
Therefore, the author of [17] extends the Software
Process Improvement and Capability Determination
(SPICE) based accreditation by an evaluation. SPICE
describes an overall process based on process attributes
and maturity levels. These represent the performance
of the individual processes, from which follows process
evaluation on a scale of 0 (incomplete) to 5 (optimizing).
The author points out that only the combination
of quantitative and qualitative evaluation ensures
a successful overall assessment of the processes.
Performance deficits can be identified through the
quantitative assessment, and possible starting points
for improvements can be derived from the qualitative
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evaluation.
Often, pure accreditation with subsequent or
preliminary evaluation is still too static, as different
stakeholders may have different sets of requirements.
To include these requirements as well, the authors
of [18] present the Business Process Blueprinting
(BPBP) method, which serves as an integrated method
for the targeted analysis, planning, design, and control
of (value-added) processes with distinctive (service)
characteristics. The method is based on the fundamental
challenge that elementary components of information
management often do not have a corresponding process
model (event-driven process chains (EPC)). Therefore,
[18] opens another opportunity to identify weak points
in processes and closes them from the perspective of
information and service management. The method looks
at the structural design of a process at different levels of
its activity, Interaction, Visibility, Internal Interaction,
Oder Penetration, and Implementation. These serve as
the foundation for an evaluation system (measurement
system), which measures internal efficiency and its
decisive influences and thus makes them measurable.
In [21], the criteria Time, Costs, Quality, Capacity,
Flexibility, Integration, and Complexity for the
evaluation of process performance are introduced.
A standardized and thus proven utility analysis does
not exist for the evaluation and accreditation of mHealth
applications. Inspired by the authors’ identification of
weaknesses of [17] and the use of different perspectives,
proposed in [18], as well as the criteria selection of [21],
our proposed methodology has emerged.
3. Methodology
3.1. Identification of integration points
An author discussion with advantages and
disadvantages along the German Fast-Track process
is conducted to identify weaknesses as they can
be considered to be potential points of integration
according to [17]. Furthermore, for this purpose, the
systematic structure of the German Fast-Track process
from different levels, as presented in [18], is analyzed
in order to evaluate the identified weaknesses later.
3.2. Evaluation of integration points
A utility analysis [19] [20] is used to assess the
effectiveness of the integration of evaluation platforms
at the possible identified positions of the integration
points. In the utility analysis, the sums of the
weighted criteria of the different integration points
are compared with each other under consideration of
different perspectives in order to be able to derive a
general recommendation for action for the integration
of evaluation platforms into the German Fast-Track
process.
Table 1. Criteria catalogue.
Criteria Description
Time • Process duration
• Idle, control, and lead time
Costs • Operating costs
• Error costs
Inter- • Standardization and automatization
operability • Process flow and accessibility
Capacity • Throughput and bottlenecks
• Workload and performance
Flexibility • Adaptability and ability to handle
changed environmental conditions
Complexity • Process structure
• Degree of interaction
We have selected criteria from the criteria catalog
that are relevant from an international perspective
[21]. The selection of criteria is presented in Table 1.
The first criterion is Time since, according to [22],
DiGAs need to be prescribable quickly, as patients
are likely to use DiGAs regardless of clinical support
or guidance, and this could cause health authorities
and providers to fall further behind. There is an
interest in saving healthcare Costs [23], and thus
resources through the use of digital solutions, which
can be assisted by proper Interoperability of systems
[24]. It could be observed whether the integration of
the DiGA evaluation platform leads to an increase in
Capacity, i.e., the number of DiGAs to be evaluated
increases. It is important to include Flexibility as
an evaluation criterion, frequently disjointed and static
solutions cannot be adequately adapted to environmental
changes or the concerns of stakeholders and lead to
problems [22]. The extent to which platforms for
evaluating the quality of DiGAs can be integrated into
the information flow and workflow of the processes is
being investigated. The goal is to achieve increased
automatization. Relevant for successful integration
is the accessibility and granularity of the information
needed by the platforms for evaluation. The final
criterion is Complexity. Reducing complexity could
result in healthcare providers being able to perform
better [23].
The scale used for the utility analysis consists of the
five nominal values very poor, poor, medium, good, and
very good. The values are mapped against the discrete
values 1 for very poor, 2 for poor, 3 for medium, 4 for
good, and 5 for very good for the later calculation of
the total values from which the ranks of the integration
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points are derived. Due to the lack of data for the
present consideration, we evaluate certain criteria on the
basis of a relative comparison between the ranks of the
integration points. The lowest rank is rated as poor, the
medium rank as medium and the highest rank as good.
The weighting scale uses the five nominal values
very low, low, medium, high and very high. The weights
are mapped against the discrete values 0% for very low,
25% for low, 50% for medium, 75% for high and 100%
for very high. Since the sum of the weights can reach
more than 100%, the values are normalized to 100% for
the comparison of the perspectives.
The implementation of the utility analysis is based
on an author discussion of the individual criteria for each
integration point. Finally, the evaluation of the criteria
is compared by different perspectives, and a general
recommendation for action is derived.
4. Identification of integration points of
DiGA evaluation platforms into the
German Fast-Track process
A systematic inspection of the German Fast-Track
process results in five formally possible integration
points. The first possible integration point is located
before the submission of the application for approval
of a DiGA by the DiGA vendor. The second possible
integration point is during the examination of the
requirements regarding the quality criteria and the
proof of the positive care effects of the DiGA by the
BfArM. The third possible integration point is after the
accreditation of the quality criteria and the proof of
positive care effects. The fourth possible integration
point is during the Plausible Justification Phase, in
which the proof of positive care effects is verified. The
fifth and final possible integration point is located after
the Plausible Justification Phase.
Integration of evaluation platforms into the
Fast-Track process can only impact the parts of the
process where accreditation of quality criteria takes
place. In the entire Fast-Track process, only during the
Examination Phase an examination of quality criteria
takes place. Therefore, we limit our consideration of
integration points to the following three of the five
possible integration points.
1. Preliminary Check
(prior to the Examination Phase, a© in Figure 2).
2. Examination Phase
(during the Examination Phase, b© in Figure 2).
3. Plausible Justification Phase
(after the Examination Phase, c© in Figure 2).
5. Evaluation of integration points of
DiGA evaluation platforms into the
German Fast-Track process
The following discussion and argumentative
considerations represent the authors’ opinion after
previous communication with the BfArM. The
assignment of the value score is exclusively due to
the authors, as no statement could be received from
the BfArM in this regard. The following criteria
are discussed holistically but evaluated based on a
worst-case scenario since this is exclusively relevant for
evaluating a possible integration point. Due to the lack
of data for the present observation, we evaluate some
criteria using a relative comparison between the ranks
of integration points.
5.1. Preliminary Check
Time: The integration of an evaluation platform in
the Preliminary Check, before the Examination Phase,
results in more time passing until the Examination
Phase begins. In the overall consideration of
downstream phases, the Examination Phase benefits
from the results of the evaluation platform, and the
upstream criteria evaluation can save time. Since only
positive care effects are examined in the remaining
phases, no further time savings are expected. Assuming
that positive care effects can be demonstrated in the
examination phase following the Preliminary Check,
time can potentially be saved to the extent of the total
process duration of up to 3 months. If positive care
effects cannot be demonstrated to a sufficient extent in
the Examination Phase, the total process duration can
run up to 15 months (Examination Phase + Plausible
Justification Phase). In this case, only time to the extent
of up to 3 months of the Examination Phase can be
saved. Assuming that no Plausible Justification Phase
is required, we rate the criterion Time for the integration
point Preliminary Check as poor since a maximum time
saving is only 20% (3 of 15 months). With the Plausible
Justification Phase’s connection, the potential savings
increase to up to 15 months (Examination Phase +
Plausible Justification Phase).
Costs: For exact costs estimation, no detailed
information about the actual costs of the BfArM is
available. Therefore, a proportional ratio of customer
costs to BfArM in-house costs is assumed. The fees
estimated by the customers can be obtained from the
BfArM’s guide for the Fast-Track process [3]. For
the evaluation of the cost criterion, the worst-case is
considered from the perspective of the DiGA vendor,
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and these are in the longest possible case up to 35700
EUR. The savings potential of integrating an evaluation
platform is assumed for the best-case scenario and
amounts up to 11100 EUR, as money can only be saved
in the Examination Phase by integrating an evaluation
platform. As a result, there is a total savings potential of
up to 31%. Due to the selected evaluation scale, which
is divided into 20% steps, the savings potential of the
criterion Costs for the integration point Preliminary
Check is rated as poor.
Capacity: With the integration of an evaluation
platform into the Preliminary Check, in the best-case,
the complete criteria check within the Examination
Phase can be omitted. Furthermore, by placing the
evaluation platform upstream of examining positive care
effects, the condition is achieved that the evaluation
platform exclusively examines quality criteria and the
BfArM exclusively examines positive care effects. An
increase in performance for the overall process can be
achieved through the specialization of the evaluation
platform with the evaluation of the criteria and the
specialization of the BfArM with the examination of the
positive care effects. Therefore, we rate the criterion
Capacity by means of relative comparison between
the integration points, the integration of an evaluation
platform in the Preliminary Check as good.
Flexibility: The criterion Flexibility receives in
comparison between the integration points the relative
rating medium since maximum flexibility is given in this
phase because all possible changes in environmental
conditions can be counteracted in the Examination
Phase without consequences due to the knowledge
gained in the Preliminary Phase.
Interoperability: The integration of an evaluation
platform in the Preliminary Check enables a high degree
of interoperability since the results of the evaluation
platform are transferred at once, directly and entirely
to the accreditation process. In relative comparison
between the integration points, we rate the criterion
Interoperability of the integration point Preliminary
Check as good.
Complexity: By integrating an evaluation platform
into the Preliminary Check, the overall process structure
of the Fast-Track process is linearized and thereby
simplified. The knowledge of the evaluation platform is
guided linearly through each further process step, which
means that the examination of the quality criteria in
the Examination Phase can be omitted. Therefore, we
rate the criterion Complexity for the integration point
Preliminary Check integration point as good.
5.2. Examination Phase
Time: Assuming that the processes can be fully
integrated and positive synergy effects occur, the
Fast-Track process can only benefit from the evaluation
platform results after they have been generated.
Therefore, the potential time savings at this point
are lower compared to the integration of evaluation
platforms in the Preliminary Check. The speed with
which the evaluation platform results are generated
determines the actual time savings. Assuming that
positive care effects have already been successfully
demonstrated in the Examination Phase, time can
potentially be saved to the extent of the total process
duration of 3 months subtracted by the time needed for
the evaluation platforms to generate results. If positive
care effects cannot be demonstrated to a sufficient extent
in the Examination Phase, or if this is clear in advance,
the total process duration can be up to 15 months. In
this case, only time within the Examination Phase can
be saved to the extent of up to 3 months subtracted by
the time needed by the evaluation platforms to generate
results. Based on the present observation, we rate the
criterion Time for the Examination Phase integration
point as very poor, since in the worst-case scenario, the
time required by the evaluation platforms to generate
results is a maximum of 3 months and thus no time
savings (0 of 3 months) are achieved.
Under the hypothetical assumption that evaluation
platforms can also demonstrate positive care effects, the
potential savings would be significantly higher at up to
15 months subtracted by the time needed for evaluation
platforms to generate results.
Costs: For exact cost estimation, no detailed
information about the actual costs of the BfArM is
available. Therefore, a proportional ratio of customer
costs to BfArM in-house costs is assumed. The fees
estimated by the customer can be obtained from the
BfArM’s guide for the Fast-Track process [3]. For the
evaluation of the criterion, the worst-case is considered
from the perspective of the DiGA vendor, and these
are in the longest possible case up to 35700 EUR. The
savings potential of integrating an evaluation platform
is assumed for the best-case scenario and amounts
to up to 11100 EUR, as costs can only be saved in
the Examination Phase by integrating an evaluation
platform. As a result, there is a total savings potential of
up to 31%. Due to the selected evaluation scale, which
is divided into 20% steps, the savings potential of the
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criterion Costs for the integration point Examination
Phase is rated as poor.
Capacity: By integrating an evaluation platform into
the Examination Phase, a part of the accreditation of
the quality criteria is eliminated since the evaluation
platform can cover it during the examination. Therefore,
we rate the criterion Capacity for the integration point
Examination Phase due to the released capacities by
means of relative comparison between the integration
points as medium.
Flexibility: Since the evaluation platform has more
interaction points in the Examination Phase than in the
Preliminary Check, more parts are affected by changes.
This fact reduces the flexibility of the Fast-Track
process to handle changes in environmental conditions
or process structure compared to the Preliminary Check.
The flexibility in the Examination Phase is lower in
direct comparison to the Plausible Justification Phase
since it has no interaction points. Therefore, we
rate the criterion Flexibility for the integration point
Examination Phase by means of relative comparison
between the integration points as poor.
Interoperability: The need for interoperability is
exceptionally high in the Examination Phase because
the accreditation process and the evaluation platform
have a high need for interaction in their examination of
the quality criteria due to the parallel process design.
Therefore, we rate the criterion Interoperability for
the integration point Examination Phase by means of
relative comparison between the integration points as
medium.
Complexity: The integration of an evaluation platform
in the Examination Phase leads to an interaction-related
complexity of the process structure due to the parallel
process of the accreditation of the quality criteria
and the evaluation of the positive care effects. By
integrating the evaluation platform into the Examination
Phase, the sub-process of accreditation of the quality
criteria can be replaced by the evaluation platform,
which increases the complexity. The integration of the
additional platform implies an increased communication
effort and a corresponding higher interoperability. In
the relative comparison between the possible integration
points, we therefore rate the criterion Complexity in the
Examination Phase as poor.
5.3. Plausibility Justification Phase
Time: The integration of an evaluation platform into
the Plausibility Justification Phase does not influence
the duration of the Fast-Track process since evaluation
platforms are usually not suitable for evaluating positive
care effects that are examined in the Plausibility
Justification Phase. Based on the present observation,
we rate the criterion Time for the integration point
Plausibility Justification Phase as very poor, since no
time savings are achieved in the worst-case scenario (0
of 12 months).
Under the hypothetical assumption that evaluation
platforms could also demonstrate positive care effects,
potential savings equal to the total process duration of
up to 12 months would be made possible.
Costs: For exact cost estimation, no detailed
information about the actual costs of the BfArM is
available. Therefore, a proportional ratio of customer
costs to BfArM in-house costs is assumed. The fees
estimated by the customer can be obtained from the
BfArM’s guide for the Fast-Track process [3]. For the
evaluation of the criterion, the worst-case is considered
from the perspective of the DiGA vendor, and these
are in the longest possible case up to 35700 EUR. The
savings potential of integrating an evaluation platform
is assumed for the best-case scenario and amounts to 0
EUR, as the integration of the evaluation platform does
not influence the Examination Phase. As a result, there
is a total savings potential of 0%. Therefore, we rate
the criterion Costs for the integration point Plausibility
Justification Phase as very poor.
Capacity: When an evaluation platform is integrated
into the Plausibility Justification Phase, interactions are
unnecessary due to the lack of need for quality criteria
evaluations. Furthermore, integration at this point has
no impact on throughput or generates any changes in
the performance of the overall process. Therefore,
in relative comparison between the integration points,
we rate the criterion Capacity for the integration point
Plausibility Justification Phase as poor.
Flexibility: Since the evaluation platform has little
or no interaction points in the Plausible Justification
Phase, no parts of the Fast-Track process are affected
by environmental changes. This fact increases the
flexibility of the Fast-Track process to handle changes in
environmental conditions or process structure compared
to the Preliminary Check. Therefore, the flexibility
in the Plausible Justification Phase is higher than
in any other integration point. Hence, we rate the
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Table 2. Utility analysis - Perspective: Integration.
Preliminary Check Examination Phase Plausible Justification Phase
Criteria Weighting Rating Score Rating Score Rating Score
Time 50% (medium) 2 (poor) 1.00 1 (very poor) 0.50 1 (very poor) 0.50
Costs 25% (low) 2 (poor) 0.50 2 (poor) 0.50 1 (very poor) 0.25
Capacity 50% (medium) 4 (good) 2.00 3 (medium) 1.50 2 (poor) 1.00
Flexibility 25% (low) 3 (medium) 0.75 2 (poor) 0.50 4 (good) 1.00
Interoperability 100% (very high) 4 (good) 4.00 3 (medium) 3.00 2 (poor) 2.00
Complexity 25% (low) 4 (good) 1.00 4 (good) 1.00 3 (medium) 0.75∑
275% 19 9.25 15 7.00 13 5.50
Normalized 100% 3.36 2.55 2.00
criterion Flexibility for the integration point Plausible
Justification Phase by means of relative comparison
between the integration points as good.
Interoperability: The need for interoperability is
low in the Plausible Justification Phase because the
examination of positive care effects does not need
interaction with an evaluation platform, as no quality
criteria are evaluated. Furthermore, integrating an
evaluation platform in this integration point has no
impact on the process flow and, therefore, no need
for standardization or automatization. Therefore, we
rate the criterion Interoperability for the integration
point Plausible Justification Phase by means of relative
comparison between the integration points as poor.
Complexity: The integration of an evaluation platform
into the Plausible Justification Phase creates a
simple process structure since the evaluation of the
quality criteria takes place linearly downstream of the
accreditation of the quality criteria in the Examination
Phase and an evaluation platform can therefore not
make a positive contribution to the overall process.
Since, in contrast to the integration of an evaluation
platform into the Preliminary Check, no positive effects
can be achieved in the Examination Phase. Therefore,
we rate the criterion Complexity for the integration
point Plausible Justification Phase by means of relative
comparison between the integration points as medium.
6. Perspectives
For the utility analysis, we consider different
integration perspectives. The Integration, Efficiency,
and Scalability perspectives are based on the assumption
of the criticisms by the German National Association
of Health Insurers that the Fast-Track process is
inadequately designed to adequately guarantee the
requirements for the factors Use-value, Quality, and
Efficiency, as outlined in [25]. In addition, we
introduce the Balance perspective, in which the criteria
are weighted equally (very high =̂ 100%) to provide
a baseline comparison between all criteria. Each
perspective, except the Balance perspective, weights the
criteria differently to reflect the selected focus.
6.1. Perspective: Integration
First, we take a look at the integration perspective.
The criterion Interoperability is the dominant factor,
with a rating of very high (very high =̂ 100%). The
criteria Time and Capacity have a higher relevance with
the rating medium (medium =̂ 50%) than the remaining
criteria, which are rated low (low =̂ 25%). The results
of this perspective are illustrated in Figure 2.
6.2. Perspective: Balance
Second, we define the Balance view in which
all evaluation criteria are equally weighted. The
resulting ranking does not differ from the ranking of the
Integration perspective, despite a slight change in the
score values, as resented in Table 3.
6.3. Perspective: Efficiency
Third, we adopt the Efficiency perspective, which
weights the two criteria of costs (very high =̂ 100%)
and time (high =̂ 100%) strongest. This weighting
expresses our focus on reducing costs and shortening
the application evaluation process. We assign medium
importance to the criteria Interoperability (medium =̂
50%) in this consideration. The remaining criteria are
weighted (low =̂ 25%).
The resulting ranking does not differ from the
ranking of the Integration perspective despite a change
in the values, as resented in Table 3.
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Table 3. Ranking of integration points according to perspectives: Integration, Balance, Efficiency, and
Scalability.
Perspective
Integration Point Integration Balance Efficiency Scalability
Rank Score Rank Score Rank Score Rank Score
Preliminary Check 1 3.36 1 6.91 1 3.18 1 4.09
Examination Phase 2 2.54 2 5.45 2 2.45 2 3.27
Plausible Justification Phase 3 2.00 3 4.73 3 1.91 3 3.00
6.4. Perspective: Scalability
Fourth, we set the focus on the Scalability
perspective. The criterion capacity has the highest
relevance and is therefore weighted as very high (very
high =̂ 100%). The criteria complexity and flexibility
also have high relevance in this perspective and are
therefore rated high (high =̂ 75%). All other criteria
have a low influence (low =̂ 25%).
The resulting ranking does not differ from the
ranking of the Integration perspective despite a change
in the values, as resented in Table 3.
7. Conclusion
7.1. Discussion of results
As a result of the utility analysis conducted to
find the best possible integration point for DiGA
evaluation platforms, we recommend the integration
point Preliminary Check due to the overall positive
effects on Time, Costs, Capacity, Interoperability, and
Complexity as represented in Table 3.
The evaluation platform can act as a gatekeeper in
this integration point and optimally save work and costs
over the entire process since the evaluation results are
available before the Fast-Track process, and therefore
the scope of the accreditation measures can be derived.
Regardless of the perspective taken, the Preliminary
Check represents the best integration point for
integrating DiGA evaluation platforms into the
German Fast-Track process. The Examination Phase
ranks second before the Plausible Justification Phase
on the third rank. As this integration point reaches the
highest score, it is preferred over the other identified
integration points.
Since the utility analysis is based on estimates
in some places, values may deviate. Although the
estimates are made to the best of the authors’ knowledge
and belief, they are naturally subject to fuzziness.
Also problematic is the relative comparison of some
criteria of the integration points with each other since
no absolute values can be determined for an exact
comparison. Furthermore, the mapping of nominal
values to numerical values is problematic. Nevertheless,
we believe that we can make a generally valid statement
despite the weaknesses of the used model, since no other
adequate method of investigation is available.
7.2. Limitations
Despite the theoretical assumption that an optimal
integration point for DiGA evaluation platforms is
known, technical and structural problems of data
integration are still an obstacle today for a concrete
implementation of a DiGA evaluation platform in the
German Fast-Track process. A special role is played by
missing or not yet implemented technical, semantical,
and syntactical standards [1] [26].
In addition, the investigation carried out in this
paper assumes that the integration of DiGA evaluation
platforms into DiGA accreditation processes, using the
German Fast-Track process as an example, produces
exclusively positive effects. The authors’ assumption is
based on the fact that the integration of such evaluation
platforms into accreditation processes is only helpful if
they produce positive effects.
7.3. Future work
This paper approach only analyzes the German
Fast-Track process. A repetition of this approach for
other DiGA accreditation processes, such as the one
of the FDA, would be desirable in order to be able
to make more generalizable statements. Furthermore,
the conceptual considerations of this paper should
be evaluated by integrating different concrete DiGA
evaluation platforms. Finally, it should be noted
that the underlying assumption of this paper, that the
integration of DiGA evaluation platforms into DiGA
accreditation processes generates only positive effects,
should be reviewed, especially concerning the question
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